These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 38361936)

  • 1. Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer.
    Xin Y; Liu CG; Zang D; Chen J
    Front Immunol; 2024; 15():1343450. PubMed ID: 38361936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
    Zhao S; Gao G; Li W; Li X; Zhao C; Jiang T; Jia Y; He Y; Li A; Su C; Ren S; Chen X; Zhou C
    Lung Cancer; 2019 Apr; 130():10-17. PubMed ID: 30885328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the relationship between intestinal microbiota and immune checkpoint inhibitors in the treatment of non-small cell lung cancer: insights from the "lung and large intestine stand in exterior-interior relationship" theory.
    Li L; Zhong H; Wang Y; Pan Z; Xu S; Li S; Zeng G; Zhang W; Li J; He L
    Front Cell Infect Microbiol; 2024; 14():1341032. PubMed ID: 38415012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.
    Jin Y; Dong H; Xia L; Yang Y; Zhu Y; Shen Y; Zheng H; Yao C; Wang Y; Lu S
    J Thorac Oncol; 2019 Aug; 14(8):1378-1389. PubMed ID: 31026576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients.
    Song P; Yang D; Wang H; Cui X; Si X; Zhang X; Zhang L
    Thorac Cancer; 2020 Jun; 11(6):1621-1632. PubMed ID: 32329229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer.
    Luo WC; Mei SQ; Huang ZJ; Chen ZH; Zhang YC; Yang MY; Liu JQ; Xu JY; Yang XR; Zhong RW; Tang LB; Yin LX; Deng Y; Peng YL; Lu C; Chen BL; Ke DX; Tu HY; Yang JJ; Xu CR; Wu YL; Zhou Q
    J Transl Med; 2024 Apr; 22(1):326. PubMed ID: 38566102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer.
    Duttagupta S; Hakozaki T; Routy B; Messaoudene M
    Curr Oncol; 2023 Oct; 30(11):9406-9427. PubMed ID: 37999101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study.
    Luciani A; Marra A; Toschi L; Cortinovis D; Fava S; Filipazzi V; Tuzi A; Cerea G; Rossi S; Perfetti V; Rossi A; Giannetta L; Sala L; Finocchiaro G; Pizzutilo EG; Carelli S; Agustoni F; Cergnul M; Zonato S; Siena S; Bidoli P; Ferrari D
    Clin Lung Cancer; 2020 Nov; 21(6):e567-e571. PubMed ID: 32591311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
    Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiome affects the response to immunotherapy in non-small cell lung cancer.
    Ren S; Feng L; Liu H; Mao Y; Yu Z
    Thorac Cancer; 2024 May; 15(14):1149-1163. PubMed ID: 38572783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiRNAs and Microbiota in Non-Small Cell Lung Cancer (NSCLC): Implications in Pathogenesis and Potential Role in Predicting Response to ICI Treatment.
    Nucera F; Ruggeri P; Spagnolo CC; Santarpia M; Ieni A; Monaco F; Tuccari G; Pioggia G; Gangemi S
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
    Kim H; Lim DH; Kwon YS; Kim MA; Park KU
    Anticancer Res; 2023 May; 43(5):2343-2349. PubMed ID: 37097676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chinese Experts Consensus on Immune Checkpoint Inhibitors 
for Non-small Cell Lung Cancer (2020 Version)].
    Zhou C; Wang J; Wang B; Cheng Y; Wang Z; Han B; Lu Y; Wu G; Zhang L; Song Y; Zhu B; Hu Y; Wang Z; Song Q; Ren S; He Y; Hu X; Zhang J; Yao Y; Zhao H; Wang Z; Chu Q; Duan J; Liu J; Qin S
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):217-235. PubMed ID: 33896153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.